• Publications
  • Influence
Novel series of 111In-labeled bombesin analogs as potential radiopharmaceuticals for specific targeting of gastrin-releasing peptide receptors expressed on human prostate cancer cells.
TLDR
These studies showed that radiometallated DOTA-X-BBN[7-14]NH(2) constructs with hydrocarbon spacers ranging from 5 to 8 carbon atoms are feasible candidates for further development as diagnostic and therapeutic radiopharmaceuticals for patients with GRP-positive cancers.
Biodistribution of filamentous phage peptide libraries in mice
TLDR
The biodistribution and clearance properties of fd-tet fifteen amino acid random peptide display libraries in fUSE5 phage in three common mouse models employed for drug discovery – CF-1, nude, and SCID mice are reported.
Radiochemical investigations of gastrin-releasing peptide receptor-specific [(99m)Tc(X)(CO)3-Dpr-Ser-Ser-Ser-Gln-Trp-Ala-Val-Gly-His-Leu-Met-(NH2)] in PC-3, tumor-bearing, rodent models: syntheses,
TLDR
Results from in vitro and in vivo models demonstrated the ability of (99m)Tc(I)-radiolabled BBN analogues to specifically target GRPrs on human, prostate, cancerous PC-3 cells.
Feasibility and safety of targeted cisplatin delivery to a select lung lobe in dogs via the AeroProbe intracorporeal nebulization catheter.
TLDR
Targeted inhaled chemotherapy could be a promising method of treatment for primary and secondary lung tumors by achieving high concentrations in the treated lobe, with lower peak serum levels than after intravenous administration.
Modification of the structure of a metallopeptide: synthesis and biological evaluation of (111)In-labeled DOTA-conjugated rhenium-cyclized alpha-MSH analogues.
Rhenium-cyclized CCMSH analogues are novel melanoma-targeting metallopeptides with high tumor uptake, long tumor retention, and low background in normal tissues, which make these metallopeptides an
Therapeutic efficacy of a 188Re-labeled alpha-melanocyte-stimulating hormone peptide analog in murine and human melanoma-bearing mouse models.
TLDR
(188)Re-(Arg(11))CCMSH appears to be a promising radiolabeled peptide for targeted radionuclide therapy of melanoma and shows significant therapeutic effects in both B16/F1 murine melanoma- and TXM13 human melanomas-bearing mouse models.
Evaluation of an (111)In-DOTA-rhenium cyclized alpha-MSH analog: a novel cyclic-peptide analog with improved tumor-targeting properties.
TLDR
The novel ReO-coordinated cyclic structure of DOTA-Re CCMSH contributes significantly to its enhanced tumor-targeting and renal clearance properties and makes DOTAReCCMSH an excellent candidate for melanoma radiodetection and radiotherapy.
Evaluation of the human melanoma targeting properties of radiolabeled alpha-melanocyte stimulating hormone peptide analogues.
TLDR
The results of this study indicate that theMC1 receptor is present on the surface of a large number of human melanoma cells, which makes the MC1 receptor a good imaging or therapeutic target, and the biodistribution properties of (188)Re-(Arg(11))CCMSH and ( 188)Re- CCMSH highlight their potential as therapeutic agents for human melan cancer.
In vivo evaluation of 188Re‐labeled alpha‐melanocyte stimulating hormone peptide analogs for melanoma therapy
TLDR
Improved tumor uptake and reduced kidney retention of 188Re‐(Arg11)CCMSH will facilitate targeted irradiation of melanoma tumors while minimizing the dose to the kidneys.
...
1
2
3
...